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1  | INTRODUC TION
The blood-brain barrier (BBB) consists primarily of endothe-
lial cells with pericytes, astrocytes and microglia on a basement 
membrane 1,2 and functions to regulate the transport of cells and 
proteins into the normal brain. Approximately 98% of therapeutic 
agents are excluded by this barrier. In several conditions, includ-
ing neurodegenerative diseases such as Alzheimer's disease (AD), 
Parkinson's disease, multiple sclerosis and amyotrophic lateral 
sclerosis (ALS), neuroinflammation can lead to BBB breakdown 
and leakiness. Endothelial progenitor cells (EPCs) migrate to the 
damaged BBB in response to hypoxia,3 trauma, growth factor 4-7 
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Abstract
In neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, 
multiple sclerosis and amyotrophic lateral sclerosis, neuroinflammation can lead to 
blood-brain barrier (BBB) breakdown. After intravenous or intra-arterial injection 
into mice, endothelial progenitor cells (EPCs) home to the damaged BBB to promote 
neurovascular repair. Autologous EPCs transfected to express specific therapeutic 
proteins offer an innovative therapeutic option. Here, we demonstrate that EPC 
transfection by electroporation with plasmids encoding the reporter protein GFP or 
an anti-β-amyloid antibody fragment (Fab) leads to secretion of each protein. We also 
demonstrate the secreted anti-β-amyloid Fab protein functions in β-amyloid aggre-
gate solubilization.
K E Y W O R D S
electroporation, endothelial progenitor cells, ex vivo cell therapy, gene therapy, β-amyloid 
disaggregation
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or chemokine secretion.8 Integration of the EPCs into the com-
promised BBB promotes neurovascular repair.9-12 EPCs can also 
be transfected ex vivo to produce therapeutic molecules such as 
antibody fragments (Fabs) directed against misfolded proteins for 
neuroprotection.
At least 26 clinical trials are registered on www.clini caltr ials.
gov using EPCs as therapeutic agents for indications such as isch-
aemic heart disease, pulmonary arterial therapy and decompen-
sated liver cirrhosis.13 Autologous EPCs transfected to express 
specific therapeutic proteins offer an option to treat these and 
other indications. Transfection can be performed using a number 
of modalities including several viruses, which can produce long-
term expression. Non-viral vectors such as plasmids can be deliv-
ered into cells by mechanical, chemical or physical means, primarily 
producing transient expression since genomic integration does not 
occur. Electroporation, a physical method, was used in this study 
because this technique does not require external reagents that 
may generate unintended consequences.
Anti-β-amyloid monoclonal antibodies (mAbs) for treatment 
of AD have been tested in several major Phase III clinical trials. 
Such antibodies against different epitopes within the biomarker 
Aβ1-42 yielded excellent results in vitro and in transgenic mice.
14-
20 Phase I and II clinical trials by AC Immune,21 Hoffmann-La 
Roche,16,22,23 Eli Lilly 17,23,24 and Biogen 19,25,26 have demon-
strated encouraging results. However, despite differences in the 
nature of these antibodies, each failed in Phase III, although later 
some therapeutic activity was demonstrated with aducanumab 
(Biogen). The cause(s) of these failures have not been clearly 
elucidated. Possible causes may be either an increasing lack of 
therapeutic significance of β-amyloid, which is very unlikely if 
we take into account the in vitro and in vivo preclinical results, 
or the fact that the mAbs do not reach their target, the β-am-
yloid deposits, in a sufficient amount. This is likely due to the 
strong filtering effect of the BBB. High doses of injected anti-
bodies (60 mg per kg body weight dose) were necessary with 
aducanumab (Biogen) to obtain a modest effect.19
We report here a novel targeted delivery system consisting 
of ex vivo transfected, autologous endothelial precursor cells 
(EPCs) capable of homing to the BBB and expressing therapeutic 
Fabs. These cells were obtained for the development of targeted 
cell-mediated gene therapy to a hypoxic site.27 EPCs are able to 
repair the damaged BBB and blood-spinal cord barrier character-
istic of neurodegenerative diseases such as AD,28 ALS,29,30 trau-
matic brain injury 31,32 or stroke 33,34 and will thus have a double 
function when combined with Fab production.
2  | MATERIAL S AND METHODS
2.1 | Cells
hCMEC/D3 blood-brain barrier endothelial cells, isolated from 
human temporal lobe microvessels and immortalized by lentiviral 
vector transduction with the catalytic subunit of human telomer-
ase (hTERT) and SV40 large T antigen, were grown in Endogro MV 
complete medium (EMD Millipore, Temecula, CA). HEPC.CB1 and 
MAgEC10.5, human and murine endothelial progenitor cell lines, 
respectively, immortalized by retroviral transduction encoding 
hTERT,35,36,37 kind gifts of C. Kieda, were grown in Optimem con-
taining 2% FBS (Gibco, Thermo Fisher Scientific) at 37°C with 5% 
CO2.
2.2 | Plasmids
Commercially available reporter plasmids encode firefly luciferase 
(gWizLuc) or enhanced green fluorescent protein (GFP, gWizGFP), 
both driven by the CMV promoter plus intron (Aldevron). pSF-
CAG.InsSP-GFP encodes the insulin secretion sequence in frame 
with enhanced GFP driven by the synthetic CAG (CMV enhancer, 
chicken beta-actin promoter and rabbit beta-globin splice acceptor 
site) promoter. To create pSF-CAG.InsSP-GFP, the OG4678 vector 
(OxGene), encoding the CAG promoter, was used as parent vector. 
PCR was performed to append the human insulin signal peptide 
to EGFP. Restriction and ligation were performed with the EGFP 
PCR product and OG4678 to create the final construct for expres-
sion and secretion of EGFP. pl.DualCAG.Hygro.cAb2789 was cre-
ated with pSF-CAG.InsSP-GFP as parent vector and encodes both 
chains of an anti-β-amyloid Fab with optimized peptide signals 
driven by dual CAG promoters. A His Tag is included to simplify 
the screening of the Fab production. The parent vector was re-
stricted and subsequently ligated with a restricted DNA fragment 
Name Pulse protocol Reference
PR0329 1p 900 V/cma  20 ms BTX protocol database, personal Communication, 
Dr Kurt Engleka, Thomas Jefferson University
PR0462 1p 625 V/cm 5 ms 41
2pPR0462 2p 625 V/cm 5 ms 
1 Hzb 
–





TA B L E  1   Electroporation protocols
     |  3HELLER Et aL.
corresponding to the ubiquitin promoter, a downstream hygromy-
cin resistance marker for cell selection and a polyadenylation se-
quence. PCR was performed to append optimized peptide signals 
to both chains of the anti-β-amyloid Fab-encoding sequences (CH1-
VH and CL-VL). In addition, a 10-His Tag encoding sequence was 
added to the heavy chain encoding sequence. Finally, the frag-
ments were subcloned into the parent vector with CAG promoters 
for both chains to create the final vector expressing and secret-
ing the anti-β-amyloid Fab. pSF-CAG.InsSP-GFP and pl.DualCAG.
Hygro.cAb2789 were verified with restriction digests and Sanger 
sequencing. All plasmids were commercially prepared with endo-
toxin levels confirm to be <100 EU/mg (Aldevron; OxGene) and 
diluted to 2 mg/mL in physiological saline.
2.3 | Transfection
Electroporation was performed in cuvettes using an ECM 830 (BTX 
Harvard Apparatus). For simplicity, cells were suspended in culture 
medium throughout the delivery. The tested pulse protocols were 
chosen from the literature (Table 1).
2.4 | Reporter assays
Luciferase activity was quantified 20 hours after transfection in 
medium containing 250 µg/mL luciferin using an Omegastar or 
Clariostar microplate reader (BMG Labtech). Intracellular GFP was 
quantified by flow cytometry (MACSQuant Analyzer 10, Miltenyi 
Biotec, Bergisch Gladbach, Germany) and FlowJo analysis soft-
ware (BD Biosciences). In brief, single HEPC.CB1 EPCs were gated 
out using the doublets discrimination analysis technique based on 
FCS and/or SSC scatter plots. GPF-positive cells among all singlets 
were then identified and analysed for their frequency and median 
fluorescent intensity (MFI). Secreted GFP in medium was quan-
tified using a FLUOstar Omega or Clariostar microplate reader 
(BMG Labtech).
2.5 | Viability assays
PrestoBlue (Invitrogen, Thermo Fisher Scientific) in medium was 
added 20 hours after transfection. After two-hour incubation, rea-
gent reduction was quantified using a FLUOstar Omega or Clariostar 
microplate reader (BMG Labtech).
2.6 | PCR
Total RNA was extracted from EPCs (PureLink RNA Micro 
kit; Invitrogen) according to the manufacturer's instructions. 
Complementary DNA was obtained by reverse transcription 
(SuperScript II Reverse Transcriptase, Invitrogen). Custom primers 
Forward 5’CTC CAA CTA CTG GAT GAA CTG GGT GAA G3’ and 
Reverse 5’CCT CGC TGG TCA GAG AGC TCA3’ (Amplification 
length: 182bp, Thermo Fisher Scientific) were validated with dilu-
tions of pl.DualCAG.Hygro.cAb2789 (100% efficiency, data not 
shown) and absolute quantification of anti-β-amyloid Fab mRNA was 
performed using real-time quantitative PCR with Power Up SYBR 
Green Master mix (Applied Biosystems) on a QuantStudio 6 (Thermo 
Fisher Scientific).
2.7 | Microscopy
MAgEC 10.5 EPCs were resuspended, counted with Luna cell count-
ing slides (Logos Biosystems, Gyeonggi-do, South Korea) and trans-
fected with pDNA as previously described. The cells were then 
transferred to CorningTM PrimariaTM 24-well plates (Thermo Fisher 
Scientific) and cultured for 48 hours at 37°C 5% CO2. The cells were 
fixed with 4% formaldehyde in PBS for 30 minutes, permeabilized 
with 0.5% Triton X-100 in PBS for 20 minutes, washed three times 
in PBS and blocked with 3% bovine serum albumin in PBS for 1 hour 
at room temperature.
Cells were stained with a chimeric human/rabbit anti-His 
Tag antibody (Sigma-Aldrich; cat# SAB5600096) at a dilution of 
1:500 in 3% BSA in PBS overnight at 4°C, washed three times in 
PBS and then incubated with Goat Anti-Human IgG antibody (Fc 
specific)−FITC antibody (Sigma-Aldrich; cat# F9512) at a dilution 
1:100 and DAPI at a dilution of 1/100 (Millipore), both prepared 
in 3% BSA in PBS for 1 hour at room temperature. The PBS was 
removed and two more washes were performed before analy-
sis for the emission of fluorescence with a digital microscope 
(CELENA S, Logos Biosystems). Alternatively, cells were stained 
with a rabbit anti-His Tag antibody (Abcam; cat# ab232492) at 
a dilution of 1:100 in 3% BSA in PBS overnight at 4°C, washed 
three times in PBS and then incubated with Goat Anti-rabbit 
IgG − AlexaFluor 488 antibody (Abcam; cat#150077) at a dilution 
1:1000 and DAPI at a dilution of 1/100 (Millipore), both prepared 
in 3% BSA in PBS for 1 hour at room temperature and processed 
as described above.
2.8 | Solubilization capacity of β-amyloid aggregates
Reaction tubes containing 30 µg of β-amyloid peptide 1-42 
(Bachem) in 10 µL of PBS, pH 7.4 (Gibco), were incubated for 
1 week at 37°C. Aggregation was measured by the thioflavin T 
(ThT)-binding assay, in which the dye's fluorescence emission in-
tensity reflects the degree of fibrillar aggregation. Disaggregation 
was followed after addition of concentrated cell supernatant, puri-
fied antibodies to the preformed fibres (10 µL each) or an irrele-
vant control antibody. The supernatant was concentrated 100-fold 
using Amicon Ultra 30 K columns (Millipore) with centrifugation 
30 minutes at 3900 g. The purified Fab and irrelevant control an-
tibody (mouse IgG) were used at a final concentration of 1.5 mg/
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mL. The reaction incubated for 2 days at 37°C. Fluorescence (exci-
tation: 450 nm; emission: 482 nm) was measured after addition of 
1 mL of ThT (3 µM in 50 mM sodium phosphate buffer, pH 6.0) on 
Fluoromax4C fluorometer (Horiba).
2.9 | Statistics
The statistical significance between the groups was determined by 
analysis of variance with Tukey-Kramer multiple comparisons test 
(GraphPad Software) or by Student's t test. A P value <.05 was con-
sidered significant.
3  | RESULTS
Since the autologous EPCs necessary for ex vivo gene therapies 
may be isolated in limited numbers, particular attention was paid to 
maintaining cell viability. With the exception of protocol ‘M’, all of 
the pulse protocols tested (Table 1) significantly affected EPC cell 
viability (Figure 1A) to varying degrees. Transgene expression after 
luciferase plasmid delivery was then compared (Figure 1B). While 
protocol PR0329 produced significant reporter expression, only 6% 
of cells survived pulse delivery. A significantly (P < .001) greater 
percentage of cells survived protocol PR0462, and a similar level 
of transgene expression was detected. Since this was a single pulse 
protocol, we performed parallel testing with two pulses (2pPR0462). 
This had the effect of increasing expression twofold while having 
no additional effect on viability. Finally, while protocol ‘M’ had no 
significant effect on viability, no reporter expression was observed. 
The mature BBB cell line hCMEC/D3 was also tested using these 
conditions. In these cells, pulsing with one or two pulses similarly de-
creased viability (Figure 1C). In this case, luciferase activity increased 
nearly threefold with the two-pulse protocol, a rate similar to that of 
EPCs (Figure 1D). Subsequent experiments were performed using 
the two-pulse version of PR0462.
A plasmid encoding GFP was designed to generate reporter 
protein secretion as a model for soluble protein therapies (pSF-
CAG.InsSP-GFP, Figure 2A). Transfection efficiency and median 
cell fluorescence were quantified by flow cytometry and com-
pared between this plasmid and a commercially available GFP plas-
mid (gWizGFP). Transfection efficiency did not vary significantly 
F I G U R E  1   Development of transfection method for human endothelial cells. A, HEPC.CB1 EPC viability after luciferase plasmid delivery 
as determined by reducing potential; B, HEPC.CB1 EPC luciferase reporter expression; n = 3-9 independent experiments. C, mature 
endothelial cell viability with protocol modification; D, mature endothelial cell luciferase reporter expression with protocol modification. 
RLU, relative luminescence units, n = 3. **P < .01; ***P < .001 statistical difference from control group. Mean ± SEM
F I G U R E  2   Transfection efficiency and confirmation of GFP 
secretion by HEPC.CB1 EPCs. A, pSF-CAG.InsSP-GFP map B, Flow 
cytometry of gWizGFP and pSF-CAG.InsSP-GFP transfected cells; 
C, median fluorescent intensity (MFI); D, secretion of GFP into 
medium. RFU, relative fluorescence units. ***P < .001 statistical 
difference from control group
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between the two plasmids, 82.6% ± 4.2% and 90.4% ± 2.4%, re-
spectively (Figure 2B). However, GFP secretion was reflected in the 
median fluorescent intensity (MFI), where the MFI of cells trans-
fected with gWizGFP was 6.6-fold (P < .001) higher than that of 
cells transfected with pSF-CAG.InsSP-GFP (Figure 2C). Secretion 
was confirmed by quantifying GFP in the medium (Figure 2D). 
GFP was not detected in the medium after gWizGFP transfection, 
while significant GFP levels were detected in the medium of EPCs 
transfected with pSF-CAG.InsSP-GFP.
Fab-encoding plasmids were designed and MAgEC 10.5 EPCs 
were transfected to test the ability of transfected EPCs to produce 
and secrete Fabs (pl.CAG. cAb2789, Figure 3A). Transgene mRNA 
was detected in the cells 48 hours after transfection (Figure 3B). 
These levels were higher after delivery of the single dual plasmid 
than after delivery of the combination of two plasmids (data not 
shown).
The presence of anti-β-amyloid Fab protein was confirmed mi-
croscopically 48 hours after transfection. Primary antibody con-
trols and pSF-CAG.InsSP-GFP transfected control cells did not 
show staining (data not shown). Non-transfected negative controls 
(Figure 3C, 3E) also did not show significant staining. Expression 
was detected in cells transfected with pl.DualCAG.Hygro.
cAb2789 using both a chimeric anti-His Tag antibody (Figure 3D) 
and a rabbit anti-His Tag antibody (Figure 3F). Therefore, both 
mRNA and protein assays confirmed the expression of the trans-
fected Fab.
An aggregate solubilization assay was used to demonstrate both 
secretion and function of the anti-β-amyloid Fab protein (Figure 4). 
Incubation of an irrelevant antibody had no effect on the aggregates. 
A significant reduction in aggregates was observed after incubation 
with either an anti-β-amyloid Fab or concentrated medium from 
transfected cells.
F I G U R E  3   Confirmation of antigen binding fragment production by MAgEC 10.5 EPCs. A, pl.DualCAG.Hygro.cAb2789 map, B, Reverse 
transcription qPCR of the cAb2789 in transfected cells, n = 3, *P < .05 statistical difference from wild type. Representative images of 
complete staining of C, non-transfected cells with chimeric anti-His Tag antibody, D, cells transfected with plasmid pl.DualCAG.Hygro.
cAb2789 with chimeric anti-His Tag antibody, E, non-transfected cells with rabbit anti-His Tag antibody, F, cells transfected with plasmid 
pl.DualCAG.Hygro.cAb2789 with rabbit anti-His Tag antibody. His Tag is shown in green; cell nuclei stained with DAPI are shown in blue
F I G U R E  4   Solubilization of β-Amyloid aggregates by 
concentrated supernatant from transfected MAgEC 10.5 EPCs, 
n = 3. Aggregates we incubated with an irrelevant antibody, 
purified anti-β-amyloid Fab protein, or with concentrated 
supernatant. ***P < .001 statistical difference from aggregates 
alone
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4  | DISCUSSION
In this study, we demonstrated that EPCs can be transfected using elec-
troporation at high efficiency with a minor loss of cell viability. Transfected 
EPCs are capable of secreting a reporter protein. Finally, we show that 
transfected EPCs can also secrete functional antibody fragments.
We first tested HEPC.CB1 EPC transfection using publicly de-
scribed pulse protocols. In the early development of electroporation 
as a delivery technique, an exponential pulse shape, essentially a ca-
pacitor discharge, was used for cell transfection. This pulse shape 
was previously tested in EPCs 38 compared with viral delivery and 
was found to be unsuitable. In this study, we chose square wave 
pulse protocols to better control cell exposure to electric pulses. 
While delivery with pulse protocol PR0329, originally developed for 
human umbilical vein endothelial cells (HUVECs), produced signif-
icant luciferase expression, it also massively reduced cell viability. 
HUVEC viability was not assayed in the original PR0329 protocol. 
The reverse was true with protocol ‘M’,39 which did not produce de-
tectable cell killing; neither did it produce detectable luciferase ex-
pression. It must be noted that protocol ‘M’ was developed for drug 
rather than for plasmid delivery to human microvascular endothelial 
cells. A pulse protocol similar to PR0462 was previously described.40 
HUVECs were suspended in a specific buffer formulation with plas-
mid and exposed 5ms pulses at a frequency of 1 Hz. While the volt-
age-to-distance ratio was similar (600 vs. 625 V/cm), a larger number 
of pulses (8) were delivered. The maximum transfection efficiency 
observed was 40% with an approximately 10% viability determined 
using microscopic morphology. Delivery with protocol PR0462 
produced some loss of cell viability, but also significant luciferase 
reporter expression. This single pulse protocol was developed for 
delivery to HUVECs, but increasing to two pulses increased lucifer-
ase levels approximately twofold while maintaining cell viability. This 
comparison was made in BBB endothelial cells with similar results. 
With two pulses, no additional effect on viability was observed, but 
luciferase levels increased 2.4-fold. This implies that this pulse pro-
tocol can reproducibly deliver pDNA across related cell types.
Transfection efficiency was quantified using two different 
plasmids encoding GFP, a classic reporter plasmid and a plasmid 
specifically designed for GFP secretion. A transfection efficiency 
of greater than 80% was observed in HEPC.CB1 EPCs using either 
of these plasmids. As expected, intracellular GFP was significantly 
lower in the plasmid designed for secretion than the classic plasmid, 
while significant levels of GFP were detected in the cell medium.
We next confirmed production and function of secreted an-
ti-β-amyloid Fab after transfection. Production of Fab mRNA was 
confirmed via qPCR while production of the Fab protein was con-
firmed microscopically. Function of the secreted anti-β-amyloid Fab 
was demonstrated using an aggregate solubilization assay. These re-
sults support the therapeutic potential of transfected EPCs.
For clinical application of this technology, long-term expression 
may be desirable for therapeutic efficacy. In that case, viral delivery, 
particularly with adeno-associated virus (AAV) is unquestionably a 
promising transfection option. Although AAV integrates preferentially 
into chromosome 19, random integration may produce insertional 
mutagenesis.41 Non-integrating AAV vectors will avoid this problem; 
however, transgene expression is diluted with cell replication.42
The purpose of the present study was the demonstration that 
early EPCs transfected ex vivo with an Fab-encoding plasmid would 
express and secrete functional Fabs that could solubilize β-amyloid 
aggregates. The work reported here constitutes the first step to-
ward a complex in vivo study aiming to demonstrate the insertion 
of injected EPCs into the mouse BBB without damage to the BBB, 
the penetration of the transfected EPCs and the secretion of the 
expressed Fabs into the brain parenchyma. This work is underway.
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